PDF(Pubmed)
Abstract：
UNASSIGNED: Halloysite nanotubes (HNTs) are a versatile and highly investigated clay mineral due to their natural availability, low cost, strong mechanical strength, biocompatibility, and binding properties. The present work explores its role for retarding and controlling the drug release from the composite polymer matrix material.
UNASSIGNED: For this purpose, nanocomposite films comprising propranolol HCl and different concentrations of HNTs were formulated using the \"solution casting method\". The menthol in a concentration of 1% w/v was used as a permeation enhancer, and its effect on release and permeation was also determined. Quality characteristics of the nanocomposite were determined, and in vitro release and permeation studies were performed using the Franz diffusion system. The data was analyzed using various mathematical models and permeation parameters. Optimized formulation was also subjected to skin irritation test, FTIR, DSC, and SEM study. Systemic absorption and disposition of propranolol HCl from the nanocomposites were predicted using the GastroPlus TCAT® model.
UNASSIGNED: The control in drug release rate was associated with the higher concentration of HNTs. F8 released 50% of propranolol within 8 hours (drug, HNTs ratio, 1:2). The optimized formulation (F6) with drug: HNTs (2:1), exhibited drug release 80% in 4 hours, with maximum flux of 145.812 µg/cm2hr. The optimized formulation was found to be a non-irritant for skin with a shelf life of 35.46 months (28-30 ℃). The in silico model predicted Cmax, Tmax, AUCt , and AUCinf as 32.113 ng/mL, 16.58 h, 942.34 ng/mL×h, and 1102.9 ng/mL×h, respectively.
UNASSIGNED: The study demonstrated that HNTs could be effectively used as rate controlling agent in matrix type transdermal formulations.
UNASSIGNED: For this purpose, nanocomposite films comprising propranolol HCl and different concentrations of HNTs were formulated using the \"solution casting method\". The menthol in a concentration of 1% w/v was used as a permeation enhancer, and its effect on release and permeation was also determined. Quality characteristics of the nanocomposite were determined, and in vitro release and permeation studies were performed using the Franz diffusion system. The data was analyzed using various mathematical models and permeation parameters. Optimized formulation was also subjected to skin irritation test, FTIR, DSC, and SEM study. Systemic absorption and disposition of propranolol HCl from the nanocomposites were predicted using the GastroPlus TCAT® model.
UNASSIGNED: The control in drug release rate was associated with the higher concentration of HNTs. F8 released 50% of propranolol within 8 hours (drug, HNTs ratio, 1:2). The optimized formulation (F6) with drug: HNTs (2:1), exhibited drug release 80% in 4 hours, with maximum flux of 145.812 µg/cm2hr. The optimized formulation was found to be a non-irritant for skin with a shelf life of 35.46 months (28-30 ℃). The in silico model predicted Cmax, Tmax, AUCt , and AUCinf as 32.113 ng/mL, 16.58 h, 942.34 ng/mL×h, and 1102.9 ng/mL×h, respectively.
UNASSIGNED: The study demonstrated that HNTs could be effectively used as rate controlling agent in matrix type transdermal formulations.
摘要：
■埃洛石纳米管（HNTs）由于其天然可用性，是一种多功能且高度研究的粘土矿物，低成本,机械强度强,生物相容性，和绑定属性。本工作探讨了其在延缓和控制药物从复合聚合物基质材料释放中的作用。
■为此，使用“溶液流延法”配制包含盐酸普萘洛尔和不同浓度的HNT的纳米复合膜。使用浓度为1%w/v的薄荷醇作为渗透促进剂，并测定了其对释放和渗透的影响。确定了纳米复合材料的质量特性，使用Franz扩散系统进行了体外释放和渗透研究。使用各种数学模型和渗透参数分析数据。优化的配方也进行了皮肤刺激试验，FTIR,DSC,和SEM研究。使用GastroPlusTCAT®模型预测纳米复合材料中普萘洛尔HCl的系统吸收和处置。
■药物释放速率的控制与较高的HNTs浓度有关。F8在8小时内释放了50％的普萘洛尔（药物，HNTs比率,1:2).优化配方（F6）与药物：HNTs（2：1），在4小时内表现出80%的药物释放，最大通量为145.812µg/cm2hr。发现优化的配方对皮肤无刺激性，保质期为35.46个月（28-30℃）。计算机模拟模型预测了Cmax，Tmax,AUCt,和AUCinf为32.113ng/mL，16.58h,942.34ng/mL×h，1102.9ng/mL×h，分别。
■研究证明HNT可有效地用作基质型透皮制剂中的速率控制剂。
■为此，使用“溶液流延法”配制包含盐酸普萘洛尔和不同浓度的HNT的纳米复合膜。使用浓度为1%w/v的薄荷醇作为渗透促进剂，并测定了其对释放和渗透的影响。确定了纳米复合材料的质量特性，使用Franz扩散系统进行了体外释放和渗透研究。使用各种数学模型和渗透参数分析数据。优化的配方也进行了皮肤刺激试验，FTIR,DSC,和SEM研究。使用GastroPlusTCAT®模型预测纳米复合材料中普萘洛尔HCl的系统吸收和处置。
■药物释放速率的控制与较高的HNTs浓度有关。F8在8小时内释放了50％的普萘洛尔（药物，HNTs比率,1:2).优化配方（F6）与药物：HNTs（2：1），在4小时内表现出80%的药物释放，最大通量为145.812µg/cm2hr。发现优化的配方对皮肤无刺激性，保质期为35.46个月（28-30℃）。计算机模拟模型预测了Cmax，Tmax,AUCt,和AUCinf为32.113ng/mL，16.58h,942.34ng/mL×h，1102.9ng/mL×h，分别。
■研究证明HNT可有效地用作基质型透皮制剂中的速率控制剂。
